As the number of healthcare innovations have increased over the years, so too have the number of M&A deals in the Pharmaceutical, Biotech and Life sciences sector. Larger companies are looking to acquire smaller operations that have found success, while smaller operations are coming together to bring game-changing medications to market.
Those who either want to acquire or divest must be mindful of the various M&A-related complexities inherent in this sector. Complicated regulations, drug pricing policies, tighter regulatory requirements, intellectual property protections and more must be considered when venturing into a transaction in the Pharmaceutical, Biotech and Life Sciences industries.
At Osler, we have worked on many major deals in this sector and advised on a wide range of transaction-related matters, including financing and strategic collaboration agreements. From large pharmaceuticals and start-up biotech firms to venture capital and private equity companies, we’ve helped players in this industry carry out their M&A strategies.
With the pandemic putting more attention on this sector than ever before, and with several medical innovations regularly coming out of this industry, there are opportunities for M&A-related growth.